"10.1371_journal.pone.0014784","plos one","2011-03-29T00:00:00Z","Ellen Piek; Klaas van der Meer; Witte J G Hoogendijk; Brenda W J H Penninx; Willem A Nolen","Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Psychiatry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands; Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands","Conceived and designed the experiments: EP KvdM WAN. Performed the experiments: EP. Analyzed the data: EP KvdM WAN. Wrote the paper: EP KvdM WAN. Critically revised the design and critically revised the manuscript: WJGH BWJHP.","E Piek: None. K van der Meer: None. WJG Hoogendijk: Lectured and advised for, and received unrestricted research grants from Ely Lilly, Lundbeck, Servier, Bristol-Myers Squibb and Organon for which payments were made to the independent research foundation of GGZ inGeest. Hoogendijk holds a patent for gene-expression profiling in peripheral blood as a biomarker for depression. All these activities are not directly related to the present study and, therefore, do not form a conflict of interest. BWJH Penninx: None. WA Nolen: received grants from the Netherlands Organisation for Health Research and Development, the European Union, the Stanley Medical Research Institute, Astra Zeneca, Eli Lilly, GlaxoSmithKline and Wyeth, received honoraria and speakers fees from Astra Zeneca, Eli Lilly, Pfizer, Servier and Wyeth, and participated in advisory boards of Astra Zeneca, Cyberonics, Pfizer and Servier.","2011","03","Ellen Piek","EP",5,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
